Headache And Episodic Neurologic Disorders

SECTION 1

Historical Context & Motivation

Headache is among the oldest documented complaints in medicine, referenced in ancient Sumerian texts and Egyptian papyri dating back thousands of years. Despite this long history, a systematic approach to classifying headache disorders only emerged in the twentieth century. For centuries, headache was attributed to humoral imbalances, demonic possession, or vascular engorgement, and treatment ranged from trepanation to bloodletting. The modern clinical framework recognizes headache as a complex neurobiological phenomenon involving peripheral and central sensitization, cortical spreading depression, and dysfunction within the trigeminovascular system. Understanding this evolution is critical for USMLE Step 2 CK, where distinguishing primary from secondary headache disorders determines the urgency of workup and management.

1672

Thomas Willis: Vascular Theory

Thomas Willis proposed that migraine arose from vasodilation of meningeal blood vessels, establishing the vascular theory of headache that persisted for three centuries.

1962

First NIH Classification

The Ad Hoc Committee on Classification of Headache published the first standardized headache classification, distinguishing vascular, tension-type, and traction headaches.

1988

ICHD-1 Published

The International Headache Society released the first edition of the International Classification of Headache Disorders (ICHD), introducing rigorous diagnostic criteria still referenced in clinical practice and board examinations.

1993

Triptan Era Begins

Sumatriptan received FDA approval, revolutionizing acute migraine treatment by targeting serotonin 5-HT₁B/₁D receptors and validating the neurovascular model of migraine pathophysiology.

2018

CGRP Monoclonal Antibodies

Erenumab became the first FDA-approved calcitonin gene-related peptide (CGRP) receptor antagonist for migraine prevention, inaugurating a new era of mechanism-based prophylaxis.

The central clinical question this lesson addresses is: Given a patient presenting with headache or an episodic neurological symptom, how do you systematically identify red flags, differentiate primary from secondary causes, and initiate appropriate management? Mastering this framework is essential for both clinical practice and high-yield board performance.

SECTION 2

Core Principles & Definitions

The foundational step in headache evaluation is determining whether the presentation is a primary headache disorder — in which headache itself is the disease — or a secondary headache disorder — in which headache is a symptom of an underlying pathological process such as subarachnoid hemorrhage, meningitis, or intracranial mass. The ICHD-3 classification organizes headache into these two broad categories and further subdivides them into specific syndromes with operationalized diagnostic criteria. An additional category, painful cranial neuropathies and other facial pains, addresses conditions like trigeminal neuralgia. Understanding these principles underpins every clinical vignette on Step 2.

Primary vs. Secondary

Primary headaches (migraine, tension-type, cluster) have no identifiable structural cause. Secondary headaches arise from an underlying condition and demand urgent investigation when red flags are present.

Red Flag Mnemonic: SNOOP₄

Systemic symptoms/signs, Neurologic signs, Onset sudden (thunderclap), Older age (>50), Pattern change, positional, papilledema, precipitated by Valsalva.

Trigeminovascular System

Pain-sensitive meningeal vessels are innervated by trigeminal C-fibers. Activation releases CGRP, substance P, and neurokinin A, producing neurogenic inflammation and peripheral sensitization — the central mechanism of migraine.

Cortical Spreading Depression

A slowly propagating wave of neuronal depolarization followed by suppression underlies migraine aura. It travels at approximately 3 mm/min across the cortex, explaining the gradual spread of visual scotomata.

Episodic Neurologic Disorders

Conditions such as epilepsy, TIA, syncope, and vertigo can mimic or co-occur with headache syndromes. Differentiating these episodic phenomena requires detailed history of temporal profile, associated features, and triggers.

✦ KEY TAKEAWAY

Think of headache evaluation like airport security screening. Most travelers (primary headaches) pass through without concern, but the screening process exists to catch the rare dangerous item (secondary headaches). The SNOOP₄ red flags are your metal detectors — they don't diagnose the threat, but they tell you when to look more closely with imaging, lumbar puncture, or other investigations.

SECTION 3

Visual Explanation: Headache Classification Flowchart

This flowchart illustrates the initial triage of a headache presentation. The first branch point — the presence or absence of SNOOP₄ red flags — determines whether the workup focuses on primary headache subtypes (left branch) or mandates urgent investigation for secondary causes (right branch). Episodic neurologic mimics are listed at the bottom.

The flowchart above represents the essential clinical algorithm tested on USMLE Step 2. When a patient presents with headache, your first task is to screen for red flags using the SNOOP₄ mnemonic. If no red flags are present, the history and physical examination will guide you toward one of the three major primary headache categories. If red flags are identified, the specific constellation of findings dictates the urgency and type of workup — a thunderclap headache reaching maximum intensity within seconds demands immediate non-contrast CT followed by lumbar puncture if imaging is negative, whereas progressive headache with papilledema warrants MRI with venography to evaluate for cerebral venous thrombosis or mass lesion. The bottom row reminds clinicians that episodic neurologic conditions such as transient ischemic attack, seizure, syncope, and vertigo can present with headache as a co-occurring or confounding symptom.

SECTION 4

Pathophysiology & Mechanisms

Migraine Pathophysiology

The contemporary understanding of migraine has shifted from a purely vascular model to a neurovascular model. The process begins with activation of the trigeminovascular system, in which peripheral sensory neurons originating from the trigeminal ganglion innervate the meningeal blood vessels and dura mater. Upon stimulation, these C-fibers release vasoactive neuropeptides — most importantly calcitonin gene-related peptide (CGRP) — which cause vasodilation, mast cell degranulation, and plasma protein extravasation, collectively termed neurogenic inflammation. Afferent signals travel to the trigeminal nucleus caudalis in the brainstem, then ascend to the thalamus and cortex, producing the conscious perception of pain. Central sensitization, characterized by allodynia and hyperalgesia, develops when repetitive nociceptive input lowers the pain threshold of second-order neurons.

Cortical Spreading Depression and Aura

In migraine with aura, the neurological symptoms are attributed to cortical spreading depression (CSD), a wave of neuronal and glial depolarization that sweeps across the cortex at approximately 3 mm/min. CSD begins in the occipital lobe in most cases, explaining the predominance of visual aura (scintillating scotomata, fortification spectra). As the wave propagates, it can produce somatosensory, language, or motor symptoms. CSD also activates trigeminal afferents, linking aura to the subsequent headache phase. Importantly, aura develops gradually over 5−60 minutes and fully resolves, distinguishing it from the abrupt onset of TIA or seizure — a high-yield distinction for boards.

Tension-Type Headache Mechanisms

The pathophysiology of tension-type headache (TTH) is less clearly defined than migraine but involves both peripheral and central mechanisms. Episodic TTH may be driven by increased pericranial myofascial tenderness and peripheral nociceptive input, while chronic TTH shows evidence of central sensitization with decreased pain thresholds on pressure algometry. Unlike migraine, TTH is not associated with CGRP release or significant neurogenic inflammation, which explains why triptans are ineffective for this condition.

Cluster Headache and Hypothalamic Activation

Cluster headache, the most severe primary headache disorder, involves activation of the posterior hypothalamus, which functions as a pacemaker for the circadian and circannual periodicity of attacks. PET imaging during cluster attacks shows increased blood flow in the ipsilateral posterior hypothalamic gray matter. The trigeminal-autonomic reflex drives the associated parasympathetic symptoms — conjunctival injection, lacrimation, nasal congestion, and ptosis/miosis — via the superior salivatory nucleus and sphenopalatine ganglion. The combination of severe unilateral orbital pain with ipsilateral autonomic features is pathognomonic for cluster headache.

This diagram illustrates the key components of migraine pathophysiology. The cortical spreading depression wave propagates across the cortex (dashed purple line), triggering aura. The trigeminal ganglion releases CGRP at meningeal vessels, producing neurogenic inflammation. Afferent signals ascend through the trigeminal nucleus caudalis and thalamus to cortical pain perception centers. Pharmacological targets are shown at the bottom.

SECTION 5

Detailed Classification of Primary Headache Disorders

USMLE Step 2 CK requires precise differentiation among the major primary headache syndromes. The table below compares migraine, tension-type headache, and cluster headache across the clinical features most commonly tested in board-style questions. Memorizing these distinguishing features is one of the highest-yield investments for the neurology section.

Comparison of the three major primary headache syndromes with diagnostic and management pearls

Feature	Migraine	Tension-Type	Cluster
Location	Unilateral (60%), frontotemporal	Bilateral, band-like	Strictly unilateral, orbital/periorbital
Quality	Pulsating/throbbing	Pressing/tightening (non-pulsating)	Boring/stabbing, excruciating
Duration	4−72 hours	30 min to 7 days	15−180 minutes
Severity	Moderate to severe	Mild to moderate	Severe to very severe
Associated Features	Nausea/vomiting, photophobia, phonophobia; ± aura	No nausea; mild photophobia OR phonophobia (not both)	Ipsilateral lacrimation, conjunctival injection, rhinorrhea, ptosis/miosis, restlessness
Behavior During Attack	Prefers dark, quiet room; lies still	Can continue activities	Agitated, paces; cannot lie still
Demographics	F > M (3:1); peak 25−55 y/o	F > M; most common primary headache	M > F (6:1); 20−40 y/o; smokers
Acute Treatment	NSAIDs, triptans, CGRP antagonists (gepants), antiemetics	NSAIDs, acetaminophen	High-flow 100% O₂, SC sumatriptan
Prophylaxis	Beta-blockers, topiramate, valproate, CGRP mAbs, amitriptyline	Amitriptyline, stress management	Verapamil (first-line), lithium, galcanezumab

⚡ HIGH-YIELD BOARD PEARL

A patient who is restless and pacing during a severe unilateral headache with tearing and rhinorrhea has cluster headache until proven otherwise. In contrast, a patient who lies motionless in a dark room with nausea and photophobia has migraine. The behavioral response to pain is the single most distinguishing clinical feature.

Secondary Headache Red Flags in Detail

Thunderclap headache (peak intensity within seconds): subarachnoid hemorrhage until proven otherwise; workup with non-contrast CT head → lumbar puncture if CT negative within 6 hours
New headache in patient >50 years: consider giant cell arteritis (temporal arteritis); check ESR/CRP, start empiric corticosteroids, temporal artery biopsy
Headache with fever and meningismus: bacterial meningitis; empiric antibiotics before LP if imaging is needed first
Progressive headache with papilledema: raised intracranial pressure from mass lesion, idiopathic intracranial hypertension, or cerebral venous sinus thrombosis
Headache worse with Valsalva or positional change: posterior fossa lesion (Chiari malformation, colloid cyst of third ventricle) or intracranial hypotension

SECTION 6

Worked Example: Clinical Vignette Analysis

The following worked example mirrors the format and complexity of a USMLE Step 2 CK clinical vignette. Work through each step to build your systematic approach to headache diagnosis and management.

Clinical Vignette: 32-Year-Old Woman with Recurrent Headaches

Step 1 — Read the Stem and Identify Key FeaturesA 32-year-old woman presents to the clinic with a 5-year history of recurrent headaches occurring 3−4 times per month. Each episode begins with flashing zigzag lines in her right visual field lasting 20 minutes, followed by a left-sided throbbing headache lasting 8−12 hours. She reports nausea, photophobia, and phonophobia during attacks. She lies in a dark room until the headache resolves. OCP use for 5 years. Neurologic examination is normal. What is the most likely diagnosis, and what is the most appropriate next step in management?

Key features extracted: recurrent, stereotyped episodes; visual aura (fortification spectra); unilateral throbbing; nausea; photo/phonophobia; prefers dark room; normal neuro exam

Step 2 — Screen for Red Flags (SNOOP₄)Apply the SNOOP₄ screening: Systemic symptoms/signs — none; Neurologic signs — normal exam; Onset — not sudden (gradual aura, then headache); Older age — patient is 32; Pattern — stable pattern over 5 years, not new or worsening. No positional component, no papilledema, no Valsalva trigger. Conclusion: no red flags are present.

SNOOP₄ screening NEGATIVE → primary headache disorder

Step 3 — Apply Diagnostic CriteriaICHD-3 criteria for migraine with aura require: (A) at least 2 attacks fulfilling criteria B−C; (B) one or more fully reversible aura symptoms (visual, sensory, speech, motor); (C) at least 3 of: aura spreads gradually over ≥5 min, two or more symptoms occur in succession, each symptom lasts 5−60 min, at least one symptom is unilateral, aura accompanied by or followed within 60 min by headache. This patient meets all criteria with her visual aura progressing over 20 minutes followed by unilateral headache with migrainous features.

Diagnosis: Migraine with aura (ICHD-3 1.2)

Step 4 — Determine ManagementWith 3−4 attacks per month causing significant disability, this patient meets criteria for both acute and prophylactic treatment. For acute therapy, a triptan (e.g., sumatriptan) taken at headache onset is first-line. For prophylaxis (indicated when ≥4 headache days/month or significant disability), options include propranolol, topiramate, or CGRP monoclonal antibodies. Critically, this patient uses oral contraceptive pills — migraine with aura is a contraindication to estrogen-containing contraceptives due to increased stroke risk. She should be counseled to switch to a progestin-only method.

Management: Acute triptan + prophylaxis + discontinue estrogen-containing OCP

Step 5 — Confirm: Is Imaging Needed?In a patient with a stable pattern of headaches meeting ICHD-3 criteria for migraine with aura and a normal neurological examination, routine neuroimaging is NOT recommended (AAN guidelines). Imaging is indicated only when red flags are present or when the headache pattern changes. This is a commonly tested point — do not order a CT or MRI for a classic migraine presentation without red flags.

No imaging indicated — classic presentation with normal exam and no red flags

SECTION 7

Headache vs. Episodic Neurologic Mimics

One of the most clinically important — and frequently tested — skills is distinguishing migraine aura from other episodic neurologic events, particularly transient ischemic attack and seizure. The temporal profile of the event is the single most useful distinguishing characteristic. A thorough understanding of these differences prevents unnecessary interventions (e.g., anticoagulation for migraine aura mistaken as TIA) and ensures timely treatment of true emergencies.

Differentiating migraine aura from TIA and focal seizure — the temporal profile is the most useful distinguishing feature

Feature	Migraine Aura	TIA	Seizure (Focal)
Onset	Gradual spread over 5−60 min	Sudden, maximal at onset	Sudden, seconds
Symptom Progression	"Marching" — spreads from one modality to next	All deficits simultaneous	"Jacksonian march" — spreads along motor/sensory cortex
Character	Positive symptoms (scintillations, tingling)	Negative symptoms (weakness, numbness, aphasia)	Positive symptoms (jerking, tingling, visual hallucination)
Duration	5−60 min per symptom	Minutes to hours (by definition <24 hrs)	Seconds to minutes
Followed by Headache	Yes, typically within 60 min	Uncommon	Postictal headache possible
Consciousness	Preserved	Preserved	May be impaired (focal to bilateral)
Key Workup	Clinical diagnosis; MRI if atypical	MRI DWI, MRA/CTA, carotid imaging, echocardiography	EEG, MRI brain

✦ KEY TAKEAWAY

Think of the three episodic neurologic phenomena as three different musical compositions. Migraine aura is a slow crescendo — building gradually over minutes with positive symptoms. TIA is a sudden silence — abrupt negative symptoms without warning. Seizure is a sudden percussive burst — explosive positive symptoms over seconds. The 'tempo' of symptom onset is your most reliable clinical clue.

SECTION 8

Connection to Advanced Concepts & Emerging Therapies

Understanding primary headache management requires familiarity not only with established therapies but also with the rapidly evolving landscape of mechanism-based treatments. The advent of CGRP-targeted therapies has transformed migraine prophylaxis and represents the first class of medications designed specifically for migraine based on pathophysiological understanding. Additionally, recognizing the overlap between headache and other episodic neurologic disorders — particularly medication overuse headache (MOH) and the concept of chronic migraine — is increasingly tested on Step 2.

Step 2 vs. advanced-level knowledge comparison

Concept	Step 2 Level	Advanced / Step 3 Level
Migraine Prophylaxis	Beta-blockers, topiramate, valproate, amitriptyline	CGRP mAbs (erenumab, fremanezumab, galcanezumab), gepants for prevention (atogepant, rimegepant)
Medication Overuse HA	Recognize ≥15 HA days/month with analgesic overuse; withdraw offending agent	Bridge therapy protocols, detoxification strategies, risk of seizures with barbiturate withdrawal
Status Migrainosus	Migraine lasting >72 hours; IV fluids, IV antiemetics, IV ketorolac	IV dihydroergotamine protocols, nerve blocks, inpatient management algorithms
Neuromodulation	Not commonly tested; know it exists as an option	Transcranial magnetic stimulation, vagus nerve stimulation, supraorbital neurostimulation (FDA-cleared devices)
Hemiplegic Migraine	Motor aura → migraine; avoid triptans due to theoretical vasoconstriction risk	Familial hemiplegic migraine: CACNA1A, ATP1A2, SCN1A channelopathies; overlap with episodic ataxia

⚠️ MEDICATION OVERUSE HEADACHE

MOH is one of the most commonly tested secondary headache diagnoses on Step 2. The diagnostic threshold is headache present ≥15 days per month with regular overuse of acute headache medication for >3 months. The threshold for 'overuse' varies: ≥10 days/month for triptans, opioids, or combination analgesics; ≥15 days/month for simple analgesics (NSAIDs, acetaminophen). The treatment is withdrawal of the overused medication combined with initiation of preventive therapy.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

A 28-year-old man presents with severe right-sided periorbital pain lasting 45 minutes, occurring nightly at 2 AM for the past 3 weeks. During attacks he paces around the room and his right eye tears profusely. What is the most likely diagnosis, and what is the first-line acute treatment?

PROBLEM 2 — BASIC CALCULATION

A 45-year-old woman reports taking ibuprofen for headaches on 18 days per month for the past 4 months. Her headaches have been worsening in frequency. She asks if she should increase her ibuprofen dose. What is the diagnosis, and what threshold defines overuse for simple analgesics versus triptans?

PROBLEM 3 — INTERMEDIATE

A 55-year-old woman with a history of well-controlled migraine presents with a new-onset headache that is different from her usual migraines. It is bilateral, worse in the morning, and associated with jaw claudication and scalp tenderness. ESR is 85 mm/hr. What is the most likely diagnosis, and what is the immediate next step before biopsy results are available?

PROBLEM 4 — APPLIED

A 40-year-old man presents to the emergency department with the worst headache of his life that reached maximum intensity within 10 seconds. He denies trauma. Non-contrast CT of the head performed 3 hours after onset is normal. What is the most appropriate next step?

PROBLEM 5 — CRITICAL THINKING

A 25-year-old woman with migraine with aura asks about starting oral contraceptive pills containing ethinyl estradiol and levonorgestrel. She also has a history of smoking 10 cigarettes per day. She wants to know if she can take this medication and if her headaches affect the decision. Discuss the risk assessment and your recommendation, citing relevant guidelines.

SUMMARY

Headache & Episodic Neurologic Disorders — Summary

Headache evaluation begins with systematic screening for red flags using the SNOOP₄ mnemonic to differentiate primary headache disorders (migraine, tension-type, cluster) from secondary headache disorders requiring urgent workup. Migraine is driven by trigeminovascular activation and CGRP release, presents with unilateral pulsating pain, nausea, and photo/phonophobia, and is treated acutely with triptans and prophylactically with beta-blockers, topiramate, or CGRP monoclonal antibodies. Tension-type headache is bilateral and pressing without significant associated features, while cluster headache is a trigeminal autonomic cephalalgia treated acutely with high-flow oxygen and subcutaneous sumatriptan, and prevented with verapamil.

Critical secondary headache scenarios include thunderclap headache (SAH workup: CT → LP), new headache in patients >50 (giant cell arteritis — start steroids immediately), and medication overuse headache (≥15 days/month for simple analgesics, ≥10 days for triptans). When differentiating episodic neurologic events, remember that migraine aura spreads gradually with positive symptoms, TIA presents suddenly with negative symptoms, and seizures produce sudden positive symptoms. Finally, always remember that migraine with aura contraindicates estrogen-containing contraceptives due to increased ischemic stroke risk.